Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. - Wikidata - wikimedia - TriplyDB

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

http://www.wikidata.org/entity/Q34683589

about

Notch signaling deregulation in multiple myeloma: A rational molecular target Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma The role of Notch and gamma-secretase inhibition in an ovarian cancer model Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.Emerging pathways as individualized therapeutic target of multiple myeloma.Notch signaling in cerebrovascular diseases (Review)Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.A role for bcl-2 in notch1-dependent transcription in thymic lymphoma cells Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.

P2860

Q26797283-7D4FC6BD-FDD3-48BE-B309-826D9FA37189 Q27027093-AE57D5D8-E1C1-40E7-A686-A792D317D396 Q34038854-40D6DF25-7979-4863-BF9B-AA1055B0D2E8 Q35636675-2EA525A7-2139-4EF1-BEEA-6A702CEC407C Q35779325-62A00E32-96DC-4BDD-958C-BCD8D079B82C Q36024533-84ADC419-833D-4CE7-850E-68852CEF46B5 Q36642956-D35CFA42-E8CE-4751-BF6D-8A267D716CDF Q37486241-F7ADEB11-7925-48AC-8151-6F8627798DE5 Q37708989-AE70542C-F562-4683-BBCB-142279026F73 Q38112176-ECEB4C43-339D-40C3-B807-B0D567A86DB4 Q38940654-9830CEBA-59E2-48BF-86B5-A2B03FDE737B Q39120190-1DCC719E-026F-47AF-94C6-49ABF79997F9 Q39203918-1433D5DA-C9EA-4147-AF72-190107DE7D2E Q39211997-A0F4944B-5C80-404A-971E-FE5A8D5CBFCC Q39449414-0557958A-8C6A-4283-BA3E-F1A754E8F002 Q40866171-583AEC4F-FB3D-4ABC-B48C-017A151A3C97 Q42117299-3CE4B1E8-2067-4BF6-A2E5-C5174845F66E Q43626781-588AC965-88C1-4942-944A-EFD84DBD4B80 Q53682262-9099ADBD-D584-40C1-AB73-41616122E34C

P2860

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

http://www.wikidata.org/entity/Q34683589

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@ast

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@en

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@nl

type

label

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@ast

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@en

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@nl

prefLabel

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@ast

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@en

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@nl

P1433

Q34683589-62AB7AD4-231F-452F-A10A-3CEACC4CE177

P1476

Q34683589-832E9B57-2219-440E-BC78-240DC6D4A2B0

P2093

Q34683589-0E320503-498C-48C7-89F7-603D73047A94

Q34683589-36D42AD9-9127-4BE6-A749-56056E723301

Q34683589-5C43F531-9B70-4B9E-A26F-D1E2C03F8E94

Q34683589-5F716F9C-6361-4A08-905F-83646BFA82EB

Q34683589-72AC8007-9E0E-49F4-92F1-C6053E341D1F

Q34683589-92DF14B8-112D-4544-89EA-7F5BEE15B0EB

Q34683589-C6A3DD1C-8B7D-42FE-B3AA-A8FC6F6C2F29

P2860

Q34683589-00C21FB9-7433-4ED0-87D9-E07032AE4309

Q34683589-021A13EE-FEB6-4BE4-8D47-B4CA4B63D643

Q34683589-0417EA8E-D685-498D-928E-C98FF6443E99

Q34683589-0BB006FC-3993-45D9-A8F7-76FB21E028C7

Q34683589-0DFEA945-A1E1-4107-9EF6-5775D3541D86

Q34683589-16D53A04-9741-48C2-A818-E3DAEBFE4407

Q34683589-24CA8B83-56A6-47B0-A7D2-EFE67983E15F

Q34683589-263C1296-6362-402D-BBDA-E1DEF7FDF9C9

Q34683589-267C402B-9BCE-4E8C-B0DF-9D775871C8A0

Q34683589-27427EA3-26AC-450C-8FE7-2DF4AF4E7DEF

P304

Q34683589-4CD87921-780C-4F02-A579-E3F28E2C066B

P31

Q34683589-BDF93DB5-89D0-44C5-99A2-6BBAD17754E2

P356

Q34683589-992D81F5-ED44-4AB0-B7AA-DF15AAB1AD71

P433

Q34683589-2C8C7AB7-76D9-4665-9AC4-949C02D4E8F7

P478

Q34683589-B61C9E98-BE56-484C-BE47-29174C99A533

P577

Q34683589-31F481F2-13A4-493A-9072-0261B53DF069

P698

Q34683589-E1B23E94-F22A-42BC-9CA1-EB7A92FAE206

P932

Q34683589-79040038-5026-4EDB-BB85-C4D58EF4EC41

P356

1535-7163.MCT-10-0372

P1433

Molecular Cancer Therapeutics

P1476

Combined inhibition of Notch s ...... ynergistic antimyeloma effect.

@en

P2093

Daniel M Sullivan

http://www.w3.org/2001/XMLSchema#string

Dmitry I Gabrilovich

http://www.w3.org/2001/XMLSchema#string

Feng Chen

http://www.w3.org/2001/XMLSchema#string

Ming Li

http://www.w3.org/2001/XMLSchema#string

Nicholas Clifton

http://www.w3.org/2001/XMLSchema#string

William S Dalton

http://www.w3.org/2001/XMLSchema#string

Yulia Nefedova

http://www.w3.org/2001/XMLSchema#string

P2860

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

Notch signaling: cell fate control and signal integration in development

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

P304

3200-3209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-10-0372

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21159606

http://www.w3.org/2001/XMLSchema#string

P932

3058809

http://www.w3.org/2001/XMLSchema#string